Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda(pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. This marks the first approval for Keytruda in the adjuvant setting and the fourth approval for its use in skin cancers. The approval was supported by data from the phase 3,…
